Payment overview · 2025
General Payments
$651.98
25 reported records · 13 companies
Healthcare provider profile · identity verified
Ali Ghazi Alamar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LA MESA, CA · NPI 1972606374
Verified facts
What the public records show
CMS Open Payments records show Ali Ghazi Alamar, M.D. received $651.98 in general payments during 2025 across 25 reported records.
Boston Scientific Corporation accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Xifaxan.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGLYZA as an associated drug or biological on 111 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Onglyza by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Edarbi by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nuedexta by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $134.46 | 20.6% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $115.72 | 17.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $111.66 | 17.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.73 | 6.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.29 | 5.4% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $34.16 | 5.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.77 | 4.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $31.20 | 4.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.52 | 4.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.43 | 4.5% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.88 | 3.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.80 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.36 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $651.98 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $145.15 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $86.60 | 3 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $76.20 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $58.26 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.91 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $31.77 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.30 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | ONGLYZA open payments reported associated product |
CMS Open Payments — General Payments 111 supporting records · 89 recipient NPIs · example record 1206133840 |
Onglyza · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
180 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 888 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 647 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 559 | 96 |
| Gabapentin | Gabapentin | 453 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 421 | 98 |
| Losartan Potassium | Losartan Potassium | 404 | 105 |
| Eliquis | Apixaban | 379 | 53 |
| Lisinopril | Lisinopril | 347 | 75 |
| Metformin Hcl | Metformin Hcl | 327 | 70 |
| Famotidine | Famotidine | 319 | 64 |
| Furosemide | Furosemide | 314 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 294 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 250 | 50 |
| Mirtazapine | Mirtazapine | 241 | 52 |
| Omeprazole | Omeprazole | 238 | 50 |
| Trazodone Hcl | Trazodone Hcl | 197 | 52 |
| Carvedilol | Carvedilol | 188 | 32 |
| Xarelto | Rivaroxaban | 180 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 40 |
| Sertraline Hcl | Sertraline Hcl | 162 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 157 | 36 |
| Potassium Chloride | Potassium Chloride | 139 | 38 |
| Jardiance | Empagliflozin | 130 | 32 |
| Levetiracetam | Levetiracetam | 126 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 35 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 123 | 35 |
| Simvastatin | Simvastatin | 120 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 43 |
| Donepezil Hcl | Donepezil Hcl | 102 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 99 | 37 |
| Memantine Hcl | Memantine Hcl | 89 | 14 |
| Alendronate Sodium | Alendronate Sodium | 85 | 17 |
| Baclofen | Baclofen | 85 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 15 |
| Myrbetriq | Mirabegron | 81 | suppressed |
| Tradjenta | Linagliptin | 80 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 76 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 17 |
| Finasteride | Finasteride | 73 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 18 |
| Cephalexin | Cephalexin | 72 | 62 |
| Bumetanide | Bumetanide | 71 | 20 |
| Pregabalin | Pregabalin | 70 | 14 |
| Olanzapine | Olanzapine | 68 | 20 |
| Risperidone | Risperidone | 68 | suppressed |
| Azithromycin | Azithromycin | 67 | 46 |
| Farxiga | Dapagliflozin Propanediol | 67 | 16 |
| Lactulose | Lactulose | 66 | 18 |
| Tramadol Hcl | Tramadol Hcl | 66 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 21 |
| Buspirone Hcl | Buspirone Hcl | 59 | 15 |
| Ezetimibe | Ezetimibe | 59 | 12 |
| Entresto | Sacubitril/Valsartan | 58 | suppressed |
| Lorazepam | Lorazepam | 56 | 21 |
| Allopurinol | Allopurinol | 54 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 54 | suppressed |
| Latanoprost | Latanoprost | 54 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 12 |
| Prednisone | Prednisone | 53 | 29 |
| Montelukast Sodium | Montelukast Sodium | 52 | suppressed |
| Mounjaro | Tirzepatide | 52 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 17 |
| Lansoprazole | Lansoprazole | 49 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 11 |
| Gemtesa | Vibegron | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Atenolol | Atenolol | 45 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Meclizine Hcl | Meclizine Hcl | 43 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 43 | 13 |
| Mupirocin | Mupirocin | 43 | 31 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 43 | suppressed |
| Nystatin | Nystatin | 42 | 20 |
| Divalproex Sodium | Divalproex Sodium | 41 | 11 |
| Alprazolam | Alprazolam | 40 | 13 |
| Clonidine Hcl | Clonidine Hcl | 40 | 15 |
| Spironolactone | Spironolactone | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 16 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 22 |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 32 | 12 |
| Ketoconazole | Ketoconazole | 32 | 12 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 11 |
| Megestrol Acetate | Megestrol Acetate | 29 | suppressed |
| Scopolamine | Scopolamine | 29 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 18 |
| Haloperidol | Haloperidol | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Clonidine | Clonidine | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Fluconazole | Fluconazole | 21 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Onglyza | Saxagliptin Hcl | 19 | suppressed |
| Vyzulta | Latanoprostene Bunod | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Trospium Chloride | Trospium Chloride | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Telmisartan | Telmisartan | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Colchicine | Colchicine | 14 | 11 |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $651.98 · 25 records | Boston Scientific Corporation | AIRSUPRA, ALVESCO, AUSTEDO XR, Cologuard Collection Kit, FARXIGA, KISUNLA, MOUNJARO, NUZYRA, REXULTI, SPRAVATO, Veozah, WATCHMAN FLX, WaveWriter Alpha Prime 16, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error